Repository: UIHistories Project: Board of Trustees Minutes - 1962 [PAGE 672]

EXTRACTED TEXT FROM PAGE:

1961]

UNIVERSITY OF ILLINOIS

669

University then reviewed the requests of Dr. Ivy together with the recommendation concerning them made by the Executive Committee of the College of Medicine. After careful consideration, the Vice-President and Provost recommended approval of the budget as originally submitted by the College of Medicine for 1961-62. including the discontinuation of the Department of Clinical Science and the reallocation to other departments of the funds and space formerly allotted to that Department. H e concurred also in the recommendation that Dr. Ivy be appointed Distinguished Professor of Physiology, Emeritus, in the Department of physiology of the College of Medicine, effective September 1, 1961. I concur in these recommendations, and they are reflected in the budgets submitted to the Board of Trustees for adoption at its meeting on August 10, 1961. In considering these recommendations concerning Dr. Ivy, I have taken into account the policy of the University of Illinois to meet as fully as resources permit the needs of professors emeriti for facilities and funds with which to continue their scholarly work although retired from active service. The acute shortage of space — especially research laboratory space —makes it virtually impossible to provide professors emeriti all of the facilities used before retirement. Similar limitations apply to other forms of support. Nevertheless, the University makes a strong effort to assist retiring faculty members to continue significant research projects, consistent with its obligations to students and to members of the faculty in active status. By way o£ further comment upon the foregoing recommendations concerning Dr. Ivy, I call to the attention of the Board of Trustees the action taken by the Seventy-second General Assembly of Illinois in adopting House Joint Resolution No, 5J. In part this resolution recommended: ". . . tliat the proponent of Krebiozen, Dr. Andrew C. Ivy, Distinguished Professor of Physiology and Head of the Clinical Science Department College of Medicine, University of Illinois, rhall continue to be Head of the Clinical Science Department and to be further provided with the necessary facilities now had and needed to further the research and testing of the drug Krebiozen in the management and control of cancer in the patient." This resolution and other communications received on behalf of Dr. Ivy's continuance in active service assume that the University of Illinois has provided continuing support for Dr. Ivy's investigations of the substance Krebiozeti as a treatment for cancer, and that his anticipated retirement on August 31, 1961, will cause this support to be terminated. This assumption is in error, since the use of the resources of the University of Illinois for research or clinical use of Krebiozen has been prohibited since November 28, 1952. (See the Minutes of the meeting of the Board of Trustees of the University of Illinois, November 28, 1952, pages 478-480.) The then President of the University announced to the Board of Trustees on November 28, 1952, that in the light of the failure of Dr. Ivy to meet specified conditions stipulated by the Board of Trustees on September Z4, 1952, "That there is to be no allowance of time, funds, space, equipment, patients or printing in behalf of any staff member of the University of Illinois for the clinical utilization of Krebiozen and that Krebiozen henceforth is to be dissociated from research or service programs." (At its meeting on September 24, 1952, the Board of Trustees had approved the recommendations of the Research Validation Committee and of the President of the University concerning the conditions to be met if further University resources were to be used in the study of the effects of Krebiozen as a treatment for cancer.) Dr. Ivy did not meet the conditions established for the continuation or resumption of the investigation of Krebiozen at the University of Illinois, and he has not requested further support from the University for such studies. So far as the administrative officers of the University are aware, no further studies of Krebiozen involving the use of University facilities, have been conducted by Dr. Ivy in his capacity as a member of the faculty of the College of Medicine and as Head of the Department of Clinical Science m that College. Hence Dr. Ivy's retirement as Head of the Department of Clinical Science would not disrupt any research on Krebiozen insofar as the University of Illinois is concerned. P r e sumably, Dr. Ivy requested the deferment of his retirement in order that he might continue his investigations on other subjects, and insofar as resources permit and in accord with its general policy in such matters, the University will assist him in